The Federal Antimonopoly Service has ordered the drug manufacturer Grotex (brand Solofram) to pay 2 billion rubles to the budget for the violation of competition, Kommersant writes. The department issued the order due to the launch of the generic Emporix based on empagliflozin, whose patent rights in Russia until 2030 belong to the German Boehringer Ingelheim. According to DSM Group, in January-September 2026, sales of drugs containing this substance in the public sector and at retail increased by 3.4% year-on-year, reaching 9.6 billion rubles.